Among the most closely watched toxicity signals in actinium-225 radiopharmaceuticals, salivary gland dose has derailed or constrained multiple programs — which makes the 4.2 Gy RBE predicted salivary gland exposure for AKY-2519 at a full therapeutic schedule of 8 MBq × 4 doses genuinely notable. For context, lutetium-177 PSMA agents already push salivary gland tolerability limits in a meaningful fraction of patients, and actinium-225’s roughly fivefold higher relative biological effectiveness amplifies that concern considerably. Aktis’ first-in-human dosimetry data from 16 mCRPC patients, using lutetium-177 AKY-2519 as a surrogate, positions this agent structurally below those benchmarks across every critical normal tissue measured.
The miniprotein scaffold is doing real work here. Unlike antibodies, which circulate for days and deliver prolonged marrow exposure, or small molecules, which clear fast but often sacrifice tumor retention, AKY-2519’s miniprotein format appears to combine rapid blood clearance with durable tumor binding — the imaging data show uptake persisting for at least six days post-administration. That retention profile is what makes the actinium-225 pairing credible: the isotope’s 10-day half-life demands a vector that stays on target long enough to deliver meaningful absorbed dose before the radioisotope decays. The predicted kidney dose of 16 Gy RBE warrants continued monitoring, but that figure sits within ranges seen with approved agents and does not represent a stop signal at this stage of development.
The B7-H3 targeting logic extends the opportunity well beyond prostate cancer. B7-H3 is broadly overexpressed in lung, colorectal, and numerous other solid tumors with limited normal tissue expression — a distribution profile that PSMA emphatically does not share. Aktis is enrolling a dedicated mCRPC Phase 1b that includes both PLUVICTO-naïve and PLUVICTO-experienced patients, which is the right design choice: it directly tests whether AKY-2519 can rescue patients who have progressed on the current standard and whether it can serve as a front-line alternative with a more favorable salivary gland profile. A second Phase 1b across other B7-H3-expressing solid tumors is planned for the second half of 2026, broadening the program’s addressable population substantially.
The single number to track from here is tumor-to-kidney absorbed dose ratio in the mCRPC Phase 1b preliminary readout expected in 2027. If AKY-2519 maintains the robust tumor retention seen in imaging while keeping kidneys at or below 16 Gy RBE at therapeutic doses, Aktis has a legitimate claim to a differentiated safety profile — and the dosimetry case for advancing to registration-enabling trials becomes straightforward.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
